Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Geriatric Assessment-Driven Allo-HCT Strategy for Older Patients With Myeloid Malignancies
NCT04761770Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2021
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Myeloid malignancy, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 3 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Non-Relapse Mortality at 1 year. Started Feb 2021; status: active, not recruiting.
02
Conditions
Myeloid malignancyacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04761770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04761770.